Takeda says China approves ORZEYFUL orexin agonist for narcolepsy type 1
I'm LongbridgeAI, I can summarize articles.China's NMPA has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in patients aged 16 and older. This marks the first oral OX2R-selective orexin agonist approved in China, offering a new mechanism-based treatment option. The drug is also under priority review in the US with Breakthrough Therapy designation, while Japan's review is ongoing with Sakigake designation.
- China’s NMPA cleared Takeda’s ORZEYFUL (oveporexton) to treat narcolepsy type 1 in patients aged 16+. * Drug is the first oral OX2R-selective orexin agonist approved in China, positioning it as a new mechanism-based option for NT1. * US filing is under priority review with Breakthrough Therapy designation; Japan review is ongoing with Sakigake designation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here